L-m Tseng
Taipei, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 27, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).
Journal: ESMO open
Published: November 14, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 21, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.
Journal: ESMO open
Published: January 22, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Journal: ESMO open
Published: November 06, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Journal: ESMO open
Published: September 27, 2022
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 25, 2019
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 10, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026